Blood sample
Biologicaldosage of anti-hinge region antibodies
NCT Number: NCT02526966
The anti-hinge region antibodies would be a relevant biomarker of IgA nephropathy. Beyond a prognostic value (which could increase the risk of Renal Absolute), the longitudinal monitoring for these antibodies could be of interest: (1) in the monitoring of patients (in place including a possible repetition renal biopsy); (2) to guide treatment decisions and (3) in clinical research, as an outcome (in substitution for the occurrence of kidney failure) in therapeutic trials IgA nephropathy.
This research project constitutes the first step in validating these antibodies biomarker of IgA nephropathy and its main objective is to study the performance of the blood levels of anti-hinge region antibodies in the diagnosis of progressive forms of histologically IgA nephropathy as defined by the Renal Risk Absolute.
The secondary objectives of this project are to establish a bio-collection that will allow us to search for other prognostic factors (genetic, cellular and serum) of IgA nephropathy and to evaluate the performance of Renal Absolute risk by integrating Oxford score, the new international histological classification.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
CH d'ANNECY, Annecy, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
dosage of anti-hinge region antibodies
Time frame: Baseline
Centre Hospitalier Universitaire de Saint Etienne
Other
Acronym: NIGA-RA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05834738
Autoimmune Diseases, Chronic Disease
Birmingham, Alabama, United States
View Trial DetailsNCT05434325
Autoimmune Diseases, Chronic Disease
Concord W., New South Wales, Australia
View Trial DetailsNCT03945318
Autoimmune Diseases, Female Urogenital Diseases
Northridge, California, United States
View Trial DetailsNCT07634744
Autoimmune Diseases, Female Urogenital Diseases
Beijing, China
View Trial Details